A carregar...
Angiotensin II Brings More Questions Than Answers
The approval of synthetic human angiotensin II (Giapreza, LaJolla Pharmaceuticals) by the FDA in December 2017 provides clinicians with a new tool in the treatment of distributive shock. Angiotensin II (ATII) was approved based on the results of the ATHOS-3 trial. In this trial, patients who receive...
Na minha lista:
| Publicado no: | P T |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MediMedia USA, Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6205124/ https://ncbi.nlm.nih.gov/pubmed/30410284 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|